Inventiva discontinues lanifibranor for systemic sclerosis

Inventiva S.A. (Euronext:IVA) discontinued development of lanifibranor (IVA337) to treat diffuse cutaneous systemic sclerosis after the product missed the primary endpoint in the Phase II FASST trial. The next-generation PPARα, PPARδ and PPARγ agonist failed to significantly reduce skin thickness as measured by the mean absolute change from baseline in modified Rodnan Skin Score (mRSS) at week 48 vs. placebo.

The double-blind, international trial enrolled 145 patients with diffuse cutaneous systemic sclerosis to receive placebo or twice-daily 400 or 600 mg doses of oral lanifibranor plus their existing standard of care (SOC) for 48 weeks...